Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

Table 2 Prognostic factors for disease-free survival (DFS): univariate analysis

	N	5-Year DFS (%) (95 % CI)	HR (95 % CI)	p-value^a
Age
< 35	30	82.6 [68.2–100]	1
≥ 35	726	90.9 [88.5–93.4]	0.5 [0.2–1.3]	0.136
SBR Grade
1–2	462	93.2 [90.5–95.9]	1
3	285	86 [81.4–91]	1.8 [1.1–2.9]	0.0138
Pathological tumor size
pT1	391	91.2 [87.9–94.5]	1
pT2	320	90 [86.2–94]	1.1 [0.7–1.8]
pT3-T4	36	88.2 [78–99.8]	1.1 [0.4–3]	0.9514
PVI
No	558	92.3 [89.7–95]	1
Yes	178	85 [79–91.4]	2.3 [1.4–3.7]	0.0007
Hormone receptors
Negative	208	86.8 [81.6–92.4]	1
Positive	526	92.5 [89.9–95.2]	0.7 [0.4–1.1]	0.1059
HER2
Negative	507	91 [88–94.1]	1
Positive	96	95.7 [91–100]	0.6 [0.2–1.6]	0.376
IHC subtypes
Luminal A	289	95.1 [92.1–98.2]	1
Luminal B/HER2-negative	82	80.1 [69.8–92]	4.3 [2–9.1]
Luminal B/HER2-positive	58	100 [100–100]	0.7 [0.2–3.3]
HER2	37	89 [77.6–100]	1.8 [0.5–6.2]
Triple-negative	127	87.6 [80.7–95]	2.6 [1.2–5.5]	0.0006